For R/M HNSCC, systemic treatments, such as immune check point inhibitor, chemotherapy, and targeted therapy against EGFR, are used as the primary approach to improve long-term disease control; however, their efficacy remains limited [36]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.